Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1949 1
1951 1
1954 1
1955 1
1958 2
1964 1
1970 2
1972 1
1973 3
1975 1
1976 1
1980 1
1981 2
1982 3
1983 1
1986 1
1987 2
1988 2
1990 2
1991 2
1992 1
1993 1
1994 1
1995 2
1996 3
1997 1
1998 1
1999 1
2000 2
2001 5
2002 7
2003 1
2004 8
2005 7
2006 9
2007 9
2008 12
2009 15
2010 24
2011 11
2012 23
2013 26
2014 14
2015 14
2016 9
2017 17
2018 8
2019 17
2020 7
2021 11
2022 7
2023 8
2024 11
2025 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

284 results

Results by year

Filters applied: . Clear all
Page 1
Remibrutinib in Chronic Spontaneous Urticaria.
Metz M, Giménez-Arnau A, Hide M, Lebwohl M, Mosnaim G, Saini S, Sussman G, Szalewski R, Haemmerle S, Lheritier K, Martzloff ED, Seko N, Wang P, Zharkov A, Maurer M; REMIX-1 and REMIX-2 Investigators; REMIX-1 Investigators; REMIX-2 Investigators. Metz M, et al. N Engl J Med. 2025 Mar 6;392(10):984-994. doi: 10.1056/NEJMoa2408792. N Engl J Med. 2025. PMID: 40043237 Clinical Trial.
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
Mepolizumab treatment in patients with severe eosinophilic asthma.
Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P; MENSA Investigators. Ortega HG, et al. N Engl J Med. 2014 Sep 25;371(13):1198-207. doi: 10.1056/NEJMoa1403290. Epub 2014 Sep 8. N Engl J Med. 2014. PMID: 25199059 Free article. Clinical Trial.
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG; ANDHI study investigators. Harrison TW, et al. Lancet Respir Med. 2021 Mar;9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8. Epub 2020 Dec 22. Lancet Respir Med. 2021. PMID: 33357499 Clinical Trial.
Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM).
Engers JL, Baker LA, Chang S, Luscombe VB, Rodriguez AL, Niswender CM, Cho HP, Bubser M, Gray AT, Jones CK, Peng W, Rook JM, Bridges TM, Boutaud O, Conn PJ, Engers DW, Lindsley CW, Temple KJ. Engers JL, et al. Among authors: bridges tm. ACS Chem Neurosci. 2024 Sep 24;15(20):3744-54. doi: 10.1021/acschemneuro.4c00465. Online ahead of print. ACS Chem Neurosci. 2024. PMID: 39316465 Free PMC article.
An Analytical Perspective on Pandemic Recovery.
Trump BD, Bridges TS, Cegan JC, Cibulsky SM, Greer SL, Jarman H, Lafferty BJ, Surette MA, Linkov I. Trump BD, et al. Among authors: bridges ts. Health Secur. 2020 May/Jun;18(3):250-256. doi: 10.1089/hs.2020.0057. Epub 2020 Jun 11. Health Secur. 2020. PMID: 32525747 Review.
Discovery of Pre-Clinical Candidate VU6008055/AF98943: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) with Robust In Vivo Efficacy.
Engers JL, Bollinger SR, Gregro AR, Capstick RA, Spearing PK, Long MF, Tarr JC, Watson KJ, Chang S, Luscombe VB, Rodriguez AL, Cho HP, Qi A, Niswender CM, Bubser M, Gould RW, Robb WH, Byun N, Gore J, Jones CK, Thomsen MS, Bridges TM, Boutaud O, Conn PJ, Engers DW, Lindsley CW, Temple KJ. Engers JL, et al. Among authors: bridges tm. ACS Chem Neurosci. 2025 Jun 4;16(11):2141-2162. doi: 10.1021/acschemneuro.5c00277. Epub 2025 May 26. ACS Chem Neurosci. 2025. PMID: 40415588 Free PMC article.
Pharmaceutical aphrodisia.
Bridges TM. Bridges TM. Curr Top Med Chem. 2007;7(11):1152. doi: 10.2174/156802607780906582. Curr Top Med Chem. 2007. PMID: 17722370 No abstract available.
Discovery of VU0467319: an M1 Positive Allosteric Modulator Candidate That Advanced into Clinical Trials.
Poslunsey MS, Wood MR, Han C, Stauffer SR, Panarese JD, Melancon BJ, Engers JL, Dickerson JW, Peng W, Noetzel MJ, Cho HP, Rodriguez AL, Hopkins CR, Morrison R, Crouch RD, Bridges TM, Blobaum AL, Boutaud O, Daniels JS, Kates MJ, Castelhano A, Rook JM, Niswender CM, Jones CK, Conn PJ, Lindsley CW. Poslunsey MS, et al. Among authors: bridges tm. ACS Chem Neurosci. 2025 Jan 1;16(1):95-107. doi: 10.1021/acschemneuro.4c00769. Epub 2024 Dec 11. ACS Chem Neurosci. 2025. PMID: 39660766 Free PMC article. Clinical Trial.
284 results